French Healthtech Resilience Raises €40 Million to Improve the Care Pathway for Cancer Patients
January 25, 2022
Europe
● Co-founded less than a year ago by two tech entrepreneurs, Céline Lazorthes and Jonathan Benhamou, in partnership with the Gustave Roussy Institute, the 5th largest cancer center in the world, Resilience’s mission is to reinvent the way we treat cancer through digital and remote medical monitoring.
● After a €5M financing in 2021, Resilience today announces a €40M Series A round led by the global investment firm Cathay Innovation with strong support from the French VC Singular. Three European funds: Exor Seeds, Picus Capital and Seaya Ventures are also participating in the round as well as a consortium of healthcare players: Fondation Santé Service, MACSF, Ramsay Santé and Vivalto Ventures.
● The ambition is clear: to create the worldwide leader in remote patient monitoring to improve the quality of life and overall survival of cancer patients, to streamline the care process and to strengthen the fundamental link with healthcare professionals.
Resilience, the healthtech company specializing in remote monitoring and therapeutic follow-up of cancer patients, announced today a new €40 million financing (Series A). This funding will allow the company to accelerate the deployment of its medical devices (CE Class IIa) in healthcare institutions and to enrich its application with new functionalities dedicated to the well-being of patients. Resilience also intends to create a foundation to fund research projects that improve patients’ adherence to treatment and their quality of life.
Experienced and committed investors, leading European funds and health sector players are investing alongside Resilience.
This fundraising is that uniquely brings together experienced investors from a broad range of backgrounds to combine their expertise to support Resilience’s rapid development.
This Series A round is led by Cathay Innovation, a global venture capital fund with a leading track record in digital health, with strong support from Singular, a French investment fund with strong European ambitions which already participated in the first €5M round in March 2021. Other prestigious investors such as Exor Seeds (an Italian family office led by John Elkann, particularly invested in technology and healthcare), Picus Capital, and Seaya Ventures (a Spanish venture capital fund founded by Beatriz González that invests in Europe and Latin America) also participated. A consortium of well-recognized players in the healthcare sector, including Fondation Santé Service, MACSF, Ramsay Santé and Vivalto Ventures completes this round.
“We are proud to have the confidence and support of seasoned and committed healthcare professionals and funding with international ambitions. We are deeply convinced, as proven by the CAPRI study, of the contribution of remote patient monitoring in oncology. We want to accelerate its adoption in health institutions and thus quickly allow patients to benefit from a better adapted, more personalized and above all, more human follow-up.” said Jonathan Benhamou & Céline Lazorthes – Co-founders of Resilience.
“Through its innovative technologies to improve patient’s quality of life and the effectiveness of therapeutic treatments, Resilience is starting a profound transformation in the fight against cancer. Our investments in digital health over years have proven to us the necessity to reinvent cancer care. We are convinced that the solutions developed by Resilience represent a major breakthrough both for patients and caregivers and we are thrilled to contribute to their deployment alongside a group of experienced and committed investors.” said Jacky Abitbol, Managing Partner at Cathay Innovation.
On a side notes: Remote therapeutic monitoring: scientifically proven results and accelerated adoption due to its coverage by Social Security
At the ASCO 2020[1] congress, the results of the CAPRI[2] (Cancérologie Parcours de soins Région Île-de-France) study were presented, providing the first scientific proof that a device combining digital technology and a new human organization significantly improves the clinical follow-up of patients treated with oral anticancer therapies. An innovative solution developed by Gustave Roussy’s research teams in 2015, CAPRI has demonstrated its ability to reduce toxicities related to side effects, which can sometimes force the reduction or interruption of treatments, and to reduce both the number and duration of hospitalizations related to these toxicities. Patients have expressed very positive feelings about CAPRI.
Since January 1, 2022, remote monitoring of chronic patients has become common law, thanks to Article 24 of the French Social Security Financing Bill (PLFSS 2022). In other words, remote monitoring is now reimbursed by Social Security.
Resilience has already deployed its solutions at the Centre Hospitalier (CH) Côte Basque, CH Valenciennes, Centre de cancérologie Les Dentellières (Valenciennes), Gustave Roussy, CHU Bordeaux and intends to strongly accelerate its adoption in 2022. It relies in particular on its partnerships with Ramsay Santé, ELSAN and Vivalto.
[1] ASCO: a major annual meeting for clinical research and innovation in oncology, the American Society of Clinical Oncology (ASCO) International Meeting held from June 4 to 8, 2021
[2] CAPRI: Digital tracking was conducted between 2016 and 2019 on a sample of 609 patients. Results include;
● A strong decrease in severe treatment-related side effects (27.6% vs. 36.9%).
● A reduction in hospitalizations (15.1% versus 22.0%)
● The length of hospital stay decreased (average of 2.82 days versus 4.44 days).
● The relative intensity dose was significantly higher with CAPRI (93.4% ± 0.26 vs 89.4% ± 0.19).
● The CAPRI intervention also improved the patient experience as measured by PACIC